source
- Induced pluripotent stem cells gain momentum as new methods and clinical successes drive drug developmentInduced pluripotent stem cells (iPSCs) are moving from a research curiosity to a practical tool in drug development. After years of steady progress, recent advances are bringing iPSCs into the spot…
- Iambic Therapeutics CEO discusses $150 million IPO and AI's evolving role in drug developmentIambic Therapeutics completed a $150 million initial public offering, raising fresh capital and seeing its share price climb to about $24.50, roughly a 50% increase from earlier in the week. CEO T…